Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 24 Hours
CMS finalized 2027 Medicare Advantage and Part D payment policies, including a major $13 billion increase in MA payments and finalized changes to the Part D risk adjustment model to differentiate payments between MA-PDs and PDPs—impacting plan revenue for various high-cost conditions and directly influencing pharmacy reimbursement strategies for VBC organizations. The evolving payment environment comes as drug manufacturers like Novo Nordisk intensify price competition, particularly in GLP-1 and insulin markets, while policy uncertainty remains around whether the Medicare pay bump will offset escalating pharmacy costs and support sustainable value-based population health initiatives. Avalere | [Bloomberg](https://links.message.bloomberg.com/a/sc/q67KNe-NWPPGZhkFWoRe3NzAkr14MTcR5vahubtpeGzoDz92pxoj2ulvk6AFzsxuAaF4Zv5heWnLot5GNIPwBUqGnv5uAJ-ZtKX3XvmSSuWzyRfwyU4tqCL-9bp2XXSbI2y6vd39MpuA_3RVFdbaYM1EPdHrp0PWLRhSR_XzvA54Sb9BaOJ7Dmvm8JjaxAw6rKu6-X71_ovjYEftifG79LS7z
Related Articles
In a first, a drugmaker’s lawsuit challenges HRSA’s 340B patient definition
In a new chapter for litigation involving the 340B Drug Pricing Program, a drugmaker is suing the federal government over the definition of patient as it pertains to the program. AbbVie Inc. says the ...
Recent 340B Court Rulings Sustain Blocked WV Law, Demand Decade-Old Federal Policy Be Set Aside
InsideHealthPolicy reports that a federal court ruled in favor of Premier Inc., vacating a decade-old HRSA policy limiting how certain 340B hospitals purchase drugs through group purchasing organizati...
Mississippi 340B law upheld by appeals court in two cases
Mississippi 340B law upheld by appeals court in two cases  American Hospital Association
Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers
Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers  Fierce Healthcare
Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safe...
Low-dose lithium treats suicidal ideation safely
A patient in his 20s recently came to see me in a state of severe distress. He described feeling consumed by his thoughts, constantly anxious, unable to function, and deeply exhausted. His sleep had c...
STAT+: 5 years after lupus breakthrough, CAR-T is still surprising autoimmunity researchers
CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.
How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey
How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey  MedCity News
A Look At CVS Health’s Valuation As Medicare Advantage Rates Rise And FTC Insulin Concerns Ease - simplywall.st
A Look At CVS Health’s Valuation As Medicare Advantage Rates Rise And FTC Insulin Concerns Ease  simplywall.st
STAT+: Biotech VCs, used to a winning formula in drug development, face disruption
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being disrupted.